Nutrien Q1 Potash Volumes Hit Record, But Guidance Holds Steady

What happened

Nutrien reported higher first-quarter adjusted EBITDA and record potash sales volumes, benefiting from tight global supply and strong demand. However, management kept full-year guidance unchanged, signaling that Middle East disruptions and farmer affordability pressures are not materially shifting their outlook. The core thesis remains anchored to potash price torque, where each $25/tonne move swings EBITDA by ±$280M. The phosphate strategic alternatives review is the critical catalyst due later in 2026, which could improve earnings quality. Despite the stock's 41% rally over the past year, the current price near $72 leaves limited margin of safety relative to the $66 attractive entry.

Implication

The Q1 results confirm strong operational execution with record potash volumes, but unchanged guidance suggests management sees persistent headwinds from farmer affordability and potential supply chain constraints. Investors should monitor whether potash volumes track the 14.1–14.8 Mt range and whether the phosphate strategic alternatives review makes concrete progress in 2026. At ~$72, the stock lacks a clear margin of safety versus the $66 attractive entry, but the bull case of phosphate monetization could push value toward $90. Accumulate on pullbacks; the stock remains a cyclical compounder if potash stays tight and the phosphate drag is removed. Judgment rating is POTENTIAL BUY with a 3.5/5 conviction, requiring re-assessment in 6–12 months.

Thesis delta

The Q1 results validate the potash-led thesis, but unchanged guidance tempers near-term upside expectations. The phosphate catalyst timeline remains the swing factor, with no new news to accelerate the timeline.